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WE investigated the influence of 2-chlorodeoxy-
adenosine (2-CdA) in combination with tumour
necrosis factor- (TNF) or its mutein VI, which
differs from the native molecule by N-terminal
amino acid composition, on the survival time of
mice inoculated with leukaemia L1210 or P388.
Groups of mice with leukaemia L1210 and P388
receiving 2-CdA combined with TNF had shorter
survival times than animals treated with these
agents separately. In contrast, the administration
of 2-CdA in conjunction with mutein VI, pro-
longed the survival of mice inoculated with these
leukaemias as compared with animals receiving
these agents separately. The results of the present
study emphasize the importance of the biological
activity of the TNFu molecule N-terminus.
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Introduction
The combination of cytokines and cytotoxic
drugs offers a new approach to increasing the
therapeutic effect in the treatment of neoplastic
diseases. There are many possible levels of inter-
actions between these two groups of anti-
neoplastic agents: cellular drug uptake, drug
target enzymes, drug metabolizing enzymes.
2-Chlorodeoxyadenosine (2-CdA) is a new
antineoplastic drug belonging to the purine ana-
logues, which is especially active in lymphoproli-
ferative disorders. Tumour necrosis factor-cz
(TNF0t), a multimodal cytokine, has a well-
known antineoplastic activity. Muteins are TNFcz
derivates, in which the first three to seven
amino acids of the native molecule have been
replaced. N-terminal amino acids play an impor-
tant role in the binding of TNF to its cell
surface receptors and in the biological activity of
this cytokine.
The results of our previous experiments
showed that both TNFcz and 2-CdA administered
separately have therapeutic activity against murine
leukaemias L1210 and P388.2’3 Our recent studies
have demonstrated that mutein VI has the best
therapeutic activity against leukaemia P388.
4
The present study was designed to compare
the influence of 2-CdA combined with TNF0t or
with its mutein VI, on murine leukaemias L1210
and P388.
(C) 1995 Rapid Communications of Oxford Ltd
Materials and Methods
Animals.. For the experiments 140 female mice,
DBA/2 strain, weighing 18-20g, 8-10 weeks
old, purchased from the Institute of Immunology
and Experimental Therapy, Polish Academy of
Sciences (Wroclaw)were used. They were given
standard laboratory food and water ad libitum.
Leukaemia: L1210 and P388 leukaemia cells were
purchased from the Institute of Immunology and
Experimental Therapy, Polish Academy of Scien-
ces (Wroclaw) and were maintained by serial
passages in the ascitic fluid of DBA/2 mice. Leu-
kaemic cells from the fluid were resuspended in
0.9% sodium chloride so that 106 L1210 or P388
cells were injected i.p. into DBA/2 recipients.
Therapeutics.. 2-CdA produced according to the
method described by Kazimierczuk et aL5 was
kindly supplied by the Foundation of Develop-
ment of Diagnosis and Therapy (Warsaw) as a
dry powder. The synthesis and analysis of TNFz
and its mutein VI were performed at the Depart-
ment of Bioorganic Chemistry, L0d2, Poland. TNF
had a specific activity of 2 x 107 U/mg. Mutein VI
was constructed using synthetic oligonucleotides
to induce changes in the cDNA encodin_ five N-
terminal amino acids of native TNF-cz. Amino
acid sequences were analysed by using auto-
mated Edman degradation with an Applied
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Table 1. The influence of 2-CdA, TNF and mutein Vl on the survival time of mice with leukaemia L1210
Therapeutics NaCI (0.9%) 2-CdA (35 mg/kg)
x ___
S.D. MS1 ILS x +_ S.D. MS7 ILS
NaCI (0.9%) 7.22 ___
0.42 7.0 10.35 ___
1.05" 10.0"
TNF
2501g/kg/24h 9.82 -I- 1.22" 10.0" 42* 7.20 0.95 7.0
400gg/kg/24h 8.20 -t- 0.83 8.0 14 6.30 ___
1.25 6.5
Mutein VI
2501g/kg/24h 8.50 0.85 8.0 14 9.50 + 1.03" 10.0"
400 gg/kg/24 h 9.35 -t- 0.90* 9.0 29 12.60 +__ 0.65* 12.5"
42*
0
-10
Experiments were performed with groups of six animals. Data represent the average of four identical experiments.
aTreatment, once a day, in eight i.p. injections.
bTreatment, four i.p. injections on days 2,4, 6, 8 of experiment.
CTreatment, once a day, in five i.p. injections.
dMean values and standard deviation.
eMedian survival time. Six mice were used per group.
ilLS
MSTof the treated group
MSTof the control group
-1 x 100(%)
*Statistical significance as compared with the control group, p < 0.05.
TNF Met-VaI-Arg-Ser-Ser-Ser-Arg-Tyr-
Mutein VI Met-Arg-Ile-Arg-Met-
FIG. 1. The n-terminal amino acids sequences of TNF and its
mutein VI.
Biosystems ABI 477A protein sequencer. The
cDNA was expressed in E. coli and the resulting
mutein was purified by ion exchange chromato-
graphy. Endotoxin contamination amounted to
approximately 1.9ng endotoxin per mg protein,
as estimated using a commercially available assay
(Sigma Chemical Co., St Louis, MO, USA).
Recombinant cytokines were reconstituted using
sterile phosphate-buffered saline (PBS).
Drugs were delivered in a volume of 0.01 ml/g
mouse weight. Control mice received equivalent
volumes of 0.99/o solution of PBS.
Antileukaemic assay: Animals received tumour
challenges on day 0. All treatments were i.p. and
were initiated on the next day. 2-CdA was admi-
nistered at dose of 35 mg/kg, once a day, for 5
days. Cytokines were administered at dose of
250 gg/kg as daily injections for 8 days or at a
dose of 400 btg/kg given 2, 4, 6 and 8 days after
the inoculation of leukaemic cells. The control
mice received i.p. injections of 0.9% NaCl.
The mice were observed daily for survival fbr a
minimum of 60 days. The median survival time
(MST) was assessed according to the equation:
MST (x + y)/2, where x denotes the earliest
day when the number of dead animals was
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>N/2, y denotes the earliest day when the
number of dead animals was > (N/2) + 1, and N
denotes the number of animals in the group.
The antileukaemic effect of the drugs (measured
as the increase in lifespan, ILS) was assessed as
the percentage ratio of MST of the treated group
(T) to that of the control group (C):
ILS--[(STT/MSTc)- 1] x 100
As each experiment was repeated four times
(six mice per group), data are reported for 24
animals per dose group.
Statistical analysis: Statistical analysis was per-
formed using Student’s t-test. Results were con-
sidered significant when p < 0.05.
Results
TNF0t given once daily, at a dose 250 lig/kg, sig-
nificantl prolonged the survival time of mice
with leukaemia L1210. Nearly the same increase
of lifespan in leukemia L1210-bearing mice was
seen in the group receiving mutein VI in the
sequential treatment schedule. Sequential applica-
tion of TNF0t at a dose of 400btg/kg and daily
application of mutein VI did not change the life-
span of leukaemia L1210-bearing mice as com-
pared with animals of the control group (Table
1).
TNF in both treatment regimes and mutein VI
given daily at a dose of 250 gg/kg caused only a
slight increase in the lifespan of P388 leukemia-
bearing mice. Sequential application of mutein VIEect of2-Cdl on murine leukaemias
Table 2. The influence of 2-CdA, TNF and mutein Vl on the survival time of mice with leukaemia P388
Therapeutics NaCI (0.9%) 2-CdA (35 mg/kg)
x S.D. MS7 ILS x -t- S.D. ILS
NaCI (0.9%) 10.25 ___
0.95 10.0 12.50 4- 1.55
TNF
250pg/kg/24h 10.82 4- 0.75 11.0 10 8.68 _+ 0.92
4001g/kg/24h 10.70 4- 0.82 10.5 5 9.22 4- 1.18
Mutein VI
250 lg/kg/24 h 11.56 4- 1.02 11.5 15 11.73 4- 0.78
400 pg/kg/24 h 13.80 4- 0.86* 14.0" 40* 15.82 4- 0.81"
12.0" 20
20
60*
Experiments were performed with groups of six animals. Data represent the average of four identical experiments.
aTreatment, once a day, in eight i.p. injections.
bTreatment, four i.p. injections on days 2,4, 6, 8 of experiment.
CTreatment, once a day, in five i.p. injections.
dMean values and standard deviation.
eMedian survival time. Six mice were used per group.
lLS
MSTof the treated group
MSTof the control group
-1 x 100(%)
*Statistical significance as compared with the control group, p < 0.05.
at a dose 400 btg/kg significantly prolonged the
survival time of mice with leukemia P388 (Table
2).
The combination of 2-CdA and TNF shortened
the survival time of animals in all treated groups.
In contrast, mice receiving 2-CdA and mutein VI
lived for a significantly longer time than did the
animals treated with these agents separately
(Tables 1 and 2).
Discussion
The interactions between cytokines and anti-
neoplastic drugs are very complex. Cytokines can
modulate the metabolism of the drug, the
expression of adhesion receptors on tumour
cells and gene expression.
7 Cytokines also have a
great influence on the host’s immune system.
TNF is a polypeptide mediator of inflammation
and cellular immune response. It also takes part
in the induction of antineoplastic activity of the
organism. The mechanism of TNF action is still
unclear. Numerous different effects of this cyto-
kine may be explained by both structural and
functional heterogeneity of TNF receptors and by
a diversification of post-receptor signal transduc-
tion pathways.
8 Although two cell surface recep-
tors for TNF, p75 and p55, have been identified
recently, the amino acid residues necessary for
the biological activity of TNF are still not
known. Klysik et al. constructed derivates of TNF
termed ’muteins’, in which the first three to
seven amino acids of native TNF were replaced
usin_ synthetic cDNA expressed in Eschechia
coll.
The aim of our study was to compare the anti-
neoplastic activity of native TNF + 2-CdA with
that of mutein VI + 2-CdA. Our previous results
have shown that among muteins III, V and VI, the
latter has the greatest activity, against murine leu-
kaemias L1210 and P388. Our results have
shown that the combination of 2-CdA and TNF
shortened the survival time of mice as compared
with that of the control group. In contrast, mice
receiving 2-CdA and mutein VI lived for a sig-
nificantly longer time than did the animals
treated with these agents separately. These results
are in agreement with our previous observations
that mice exhibit much better tolerance to high
doses of mutein VI as compared with native
TNF.4 From other data’9 it is known that N-term-
inal amino acids are critical for both receptor
binding and biological activity of TNF. Tch6r-
zewski et al. have revealed that mutein VI fails to
recognize both TNF receptors. It also fails to
increase secretion of cytokines IL-1, IL-6, GM-
CSF and IFN-,, or to activate granulocytes, but it
has the highest cytotoxic activity.’9 This may
suggest an alternative mechanism of action.
TNF may cause tissue damage by augmenting
neutrophil function, both by directly activating
neutrophils and by affecting their response to
other stimuli.9 The lack of these effects after the
addition of mutein VI may explain the lower
toxicity when combined with 2-CdA as com-
pared with the combination of native TNF and
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It is well known that TNF acts synergistically
with topoisomerase target drugs (adriamycin,
amsacrine, mitoxantron, etoposide, teniposide).
This effect is probably related to the increase in
the activity of topoisomerase I and II, resulting in
enhanced DNA strand breaks and cleavage
complex] In contrast, TNF does not enhance the
antineoplastic effects of bleomycin, hydroxyurea,
ara-C, cis-platin, mitomycin, vincristine and vin-
blastine.
7 Warzocha et al. have shown that TNF
potentiates the antineoplastic activity of cyclo-
phosphamide and methotrexate.
2 The studies of
Winkelhake et al. have shown that the combina-
tion of TNFa and interleukin-2 does not increase
the lifespan of L1210 leukaemia-bearing mice,
compared with animals treated with these agents
separately,m The results of our previous experi-
ments revealed that 2-CdA and interferon-a show
an additive inhibitory effect on the growth of clo-
nogenic leukaemic blasts in vitro.
11
The mechanism of action of 2-CdA is still
unclear, but it may be related to the activation of
apoptosis.
12 Apoptosis (programmed cell death)
represents a mechanism of cell removal in
embryonic development and in controlling cell
populations. Defects of this process may be
involved in the production of neoplasms. Apop-
tosis may be induced by many factors, one of
them being TNF. 13’14 TNF-activated protein
kinase C appears to be involved in the induction
of the c-jun, proto-oncogene which seems to be
involved in apoptosis.
4-- Induction of c-jun
transcription is also observed in the treatment of
myeloid leukaemia cells with new purine analo-
gues, which have also been shown to induce
apoptosis.
17 These observations may explain the
synergistic action of 2-CdA and the TNF deriva-
tive, mutein VI.
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